Targeting DYRK1A with rationally designed pyrazine-guanidine hybrids for Alzheimer's disease: design, synthesis, and biological evaluation.

Khan S, Khan S, Khan S, Rahman MA, Rahman A, Reza A, Khurana S, Ashraf MZ, Islam A, Hoda N

DOI: 10.1039/d6ra06655k
Published: 2026 Sep 23
Container: RSC advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1039/d6ra06655k,
  title = {Targeting DYRK1A with rationally designed pyrazine-guanidine hybrids for Alzheimer's disease: design, synthesis, and biological evaluation.},
  author = {Khan S and Khan S and Khan S and Rahman MA and Rahman A and Reza A and Khurana S and Ashraf MZ and Islam A and Hoda N},
  year = {2026},
  journal = {RSC advances},
  doi = {10.1039/d6ra06655k},
  url = {https://doi.org/10.1039/d6ra06655k}
}

RIS

TY  - JOUR
TI  - Targeting DYRK1A with rationally designed pyrazine-guanidine hybrids for Alzheimer's disease: design, synthesis, and biological evaluation.
AU  - Khan S
AU  - Khan S
AU  - Khan S
AU  - Rahman MA
AU  - Rahman A
AU  - Reza A
AU  - Khurana S
AU  - Ashraf MZ
AU  - Islam A
AU  - Hoda N
PY  - 2026
JO  - RSC advances
DO  - 10.1039/d6ra06655k
UR  - https://doi.org/10.1039/d6ra06655k
ER  -

APA

S, K., S, K., S, K., MA, R., A, R., A, R., S, K., MZ, A., A, I., & N, H. (2026). Targeting DYRK1A with rationally designed pyrazine-guanidine hybrids for Alzheimer's disease: design, synthesis, and biological evaluation.. RSC advances. https://doi.org/10.1039/d6ra06655k

Source records

pubmed · retrieved 2026-09-25T19:53:48.580Z